The new EU Medical Device Regulation (MDR) 2017/745, which will come into full effect in May 2021, has a major impact on medical device manufacturers worldwide. Implementation of the new regulations has manufacturers facing challenges due to the stricter rules, limited resources, and lack of clear EU guidance. Therefore, we are especially proud to announce that Thirona successfully implemented the requirements and we are now certified against the new MDR.

Thirona has obtained an exclusive license on a patent in relation to Cystic Fibrosis (CF),  a rare genetic condition that creates lung abnormalities from a very early age. The patent allows us to develop an AI algorithm that will analyse CT scans to identify even the smallest abnormalities in the lungs, especially early on, ensuring that the right treatment can follow.

Public-private consortium P4O2 (Precision Medicine for more Oxygen) investigates risk factors for developing lung damage and chronic complaints after COVID-19  30 September 2020 Many patients who have had COVID-19 continue [...]